EP624 Non-endometrioid adenocarcinoma of the uterine corpus: clinicopathological results and treatment outcomes

Introduction/Background Uterine corpus cancer is the most common gynecological malignancy in developed countries and the second most common after cancer cervix in developing countries. Non-Endometrioid malignancies have higher risks for recurrence and distant metastasis that may address the need for adjuvant therapy. In this study, we investigated different prognostic factors, clinic-pathological data and treatment outcome to try to find the best treatment modality and its effect on survival. Methodology A total of 76 patients with Non-endometrioid adenocarcinoma were treated in NCI, Cairo University (2009–2013). In which the treatment options, Histological and prognostic factors were correlated to OS and DFS. Results The median age at presentation was 62 years. The most frequently encountered pathology was Carcinosarcoma (48.7%) followed by papillary serous carcinoma (36.8%). The 3 years & 5 years OS for the whole group of Non-Endometrioid adenocarcinoma were 35.9±5.6% & 17.5%±5.6% respectively and with a median OS of 22.2±3.3 month. Adjuvant radiotherapy (P=0.007), Lymph node negativity (P=0.005) and early stage I/II (P≤0.0001) had a statistically significant improvement in OS. While the 3 years & 5 years DFS for the whole group of Non-Endometrioid adenocarcinoma were 79.6%±7.5% & 30.6%±11% respectively and with a median DFS of 46.6 month. When comparing patients with Non-Endometrioid adenocarcinoma who underwent surgery alone VS surgery followed by adjuvant treatment, there was a trend for a better median OS (14.1±1.3 VS 35.1±7.1) and it was statistically significant (p-value=0.002). Conclusion Multivariate analysis revealed that Adjuvant radiotherapy, Lymph node negativity and early stage I/II had a statistically significant impact on OS. On the other hand, there was no significance encountered with the remaining factors. Due to the high incidence of systemic relapse, adjuvant treatment and more in-depth analysis is needed for better management of those high-risk groups of patients. Disclosure Nothing to disclose.